An update on diabetes related skeletal fragility

References

• Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes–a meta-analysis. Osteoporos Int 2007;18:427-44
   PubMed Web of Science ®Google Scholar
• Hofbauer LC, Brueck CC, Singh SK, et al. Osteoporosis in patients with diabetes mellitus. J Bone Miner Res 2007;22:1317-28
   PubMed Web of Science ®Google Scholar
• Hothersall EJ, Livingstone SJ, Looker HC, et al. Contemporary risk of hip fracture in type 1 and type 2 diabetes: a national registry study from Scotland. J Bone Miner Res 2014;29:1054-60
   PubMed Web of Science ®Google Scholar
• Janghorbani M, Van Dam RM, Willett WC, et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007;166:495-505
   PubMed Web of Science ®Google Scholar
• Dhaliwal R, Cibula D, Ghosh C, et al. Bone quality assessment in type 2 diabetes mellitus. Osteoporos Int 2014;25:1969-73
   PubMed Web of Science ®Google Scholar
• Starup-Linde J, Eriksen SA, Lykkeboe S, et al. Biochemical markers of bone turnover in diabetes patients–a meta-analysis, and a methodological study on the effects of glucose on bone markers. Osteoporos Int 2014;25:1697-708
   PubMed Web of Science ®Google Scholar
• Cheng X, Ni B, Zhang Z, et al. Polyol pathway mediates enhanced degradation of extracellular matrix Via p38 MAPK activation in intervertebral disc of diabetic rats. Connect Tissue Res 2012;54:118-22
   Google Scholar
• Inaba M. Influence of high glucose on 1,25-dihydroxyvitamin D3-induced effect on human osteoblast-like MG-63 cells. J Bone Miner Res 1995;10:1050-6
   PubMedGoogle Scholar
• Cunha JS, Ferreira VM, Maquigussa E, et al. Effects of high glucose and high insulin concentrations on osteoblast function in vitro. Cell Tissue Res 2014;358:249-56
   PubMed Web of Science ®Google Scholar
• Botolin S, McCabe LR. Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways. J Cell Biochem 2006;99:411-24
   PubMed Web of Science ®Google Scholar
• Hamada Y, Fujii H, Fukagawa M. Role of oxidative stress in diabetic bone disorder. Bone 2009;45(Suppl 1):S35-8
   Google Scholar
• McCarthy AD, Etcheverry SB, Cortizo AM. Effect of advanced glycation endproducts on the secretion of insulin-like growth factor-I and its binding proteins: role in osteoblast development. Acta Diabetol 2001;38:113-22
   PubMedGoogle Scholar
• Yamamoto T, Ozono K, Miyauchi A, et al. Role of advanced glycation end products in adynamic bone disease in patients with diabetic nephropathy. Am J Kidney Dis 2001;38:S161-4
   PubMed Web of Science ®Google Scholar
• Bohlender JM, Franke S, Stein G, et al. Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 2005;289:F645-59
   PubMed Web of Science ®Google Scholar
• Vashishth D, Gibson GJ, Khoury JI, et al. Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone 2001;28:195-201
   PubMed Web of Science ®Google Scholar
• Silva MJ, Brodt MD, Lynch MA, et al. Type 1 diabetes in young rats leads to progressive trabecular bone loss, cessation of cortical bone growth, and diminished whole bone strength and fatigue life. J Bone Miner Res 2009;24:1618-27
   PubMed Web of Science ®Google Scholar
• Schwartz AV, Garnero P, Hillier TA, et al. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab 2009;94:2380-6
   PubMed Web of Science ®Google Scholar
• Saito M, Kida Y, Kato S, et al. Diabetes, collagen, and bone quality. Curr Osteoporos Rep 2014;12:181-8
   PubMed Web of Science ®Google Scholar
• Saito M, Fujii K, Mori Y, et al. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int 2006;17:1514-23
   PubMed Web of Science ®Google Scholar
• Tomasek JJ, Meyers SW, Basinger JB, et al. Diabetic and age-related enhancement of collagen-linked fluorescence in cortical bones of rats. Life Sci 1994;55:855-61
   PubMedGoogle Scholar
• Hein GE. Glycation endproducts in osteoporosis[mdash]is there a pathophysiologic importance? Clin Chim Acta 2006;371:32-6
   PubMed Web of Science ®Google Scholar
• Kume S, Kato S, Yamagishi S, et al. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res 2005;20:1647-58
   PubMed Web of Science ®Google Scholar
• Stolzing A, Sellers D, Llewelyn O, et al. Diabetes induced changes in rat mesenchymal stem cells. Cells Tissues Organs 2010;191:453-65
   PubMed Web of Science ®Google Scholar
• Okazaki K, Yamaguchi T, Tanaka K-I, et al. Advanced glycation end products (AGEs), but not high glucose, inhibit the osteoblastic differentiation of mouse stromal ST2 cells through the suppression of osterix expression, and inhibit cell growth and increasing cell apoptosis. Calcif Tissue Int 2012;91:286-96
   PubMedGoogle Scholar
• Weinberg E, Maymon T, Weinreb M. AGEs induce caspase-mediated apoptosis of rat BMSCs via TNFα production and oxidative stress. J Mol Endocrinol 2014;52:67-76
   PubMed Web of Science ®Google Scholar
• Coe LM, Lippner D, Perez GI, et al. Caspase-2 deficiency protects mice from diabetes-induced marrow adiposity. J Cell Biochem 2011;112:2403-11
   PubMedGoogle Scholar
• Miyata T, Notoya K, Yoshida K, et al. Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J Am Soc Nephrol 1997;8:260-70
   PubMed Web of Science ®Google Scholar
• Valcourt U, Merle B, Gineyts E, et al. Non-enzymatic glycation of bone collagen modifies osteoclastic activity and differentiation. J Biol Chem 2007;282:5691-703
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Yamaguchi T, Yamauchi M, et al. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2008;93:1013-19
   PubMedGoogle Scholar
• Keats E, Khan ZA. Unique responses of stem cell-derived vascular endothelial and mesenchymal cells to high levels of glucose. PLoS One 2012;7:e38752
   Web of Science ®Google Scholar
• Botolin S, McCabe LR. Bone loss and increased bone adiposity in spontaneous and pharmacologically induced diabetic mice. Endocrinology 2007;148:198-205
   PubMed Web of Science ®Google Scholar
• Chuang CC, Yang RS, Tsai KS, et al. Hyperglycemia enhances adipogenic induction of lipid accumulation: involvement of extracellular signal-regulated protein kinase 1/2, phosphoinositide 3-kinase/Akt, and peroxisome proliferator-activated receptor gamma signaling. Endocrinology 2007;148:4267-75
   PubMed Web of Science ®Google Scholar
• Barbagallo I, Vanella A, Peterson SJ, et al. Overexpression of heme oxygenase-1 increases human osteoblast stem cell differentiation. J Bone Miner Metab 2010;28:276-88
   PubMed Web of Science ®Google Scholar
• Keats EC, Dominguez JM, Grant MB, et al. Switch from canonical to noncanonical Wnt signaling mediates high glucose-induced adipogenesis. Stem Cells 2014;32:1649-60
   Google Scholar
• Wang A, Midura RJ, Vasanji A, et al. Hyperglycemia diverts dividing osteoblastic precursor cells to an adipogenic pathway and induces synthesis of a hyaluronan matrix that is adhesive for monocytes. J Biol Chem 2014;289:11410-20
   Google Scholar
• Hough S, Russell JE, Teitelbaum SL, et al. Calcium homeostasis in chronic streptozotocin-induced diabetes mellitus in the rat. Am J Physiol 1982;242:E451-6
   PubMed Web of Science ®Google Scholar
• Ikeda K, Matsumoto T, Morita K, et al. The role of insulin in the stimulation of renal 1,25-dihydroxyvitamin D synthesis by parathyroid hormone in rats. Endocrinology 1987;121:1721-6
   PubMedGoogle Scholar
• Levy JR, Murray E, Manolagas S, et al. Demonstration of insulin receptors and modulation of alkaline phosphatase activity by insulin in rat osteoblastic cells. Endocrinology 1986;119:1786-92
   PubMedGoogle Scholar
• Thomas DM, Hards DK, Rogers SD, et al. Insulin receptor expression in bone. J Bone Miner Res 1996;11:1312-20
   PubMed Web of Science ®Google Scholar
• Hahn TJ, Westbrook SL, Sullivan TL, et al. Glucose transport in osteoblast-enriched bone explants: characterization and insulin regulation. J Bone Miner Res 1988;3:359-65
   PubMedGoogle Scholar
• Canalis E. Effect of hormones and growth factors on alkaline phosphatase activity and collagen synthesis in cultured rat calvariae. Metabolism 1983;32:14-20
   PubMed Web of Science ®Google Scholar
• Pun KK. The importance of parathyroid hormone in inhibition of collagen synthesis and mitogenesis of osteoblastic cell. J Biochem 1989;106:1090-3
   PubMedGoogle Scholar
• Wergedal JE, Baylink DJ. Characterization of cells isolated and cultured from human bone. Proc Soc Exp Biol Med 1984;176:60-9
   PubMed Web of Science ®Google Scholar
• Maor G, Karnieli E. The insulin-sensitive glucose transporter (GLUT4) is involved in early bone growth in control and diabetic mice, but is regulated through the insulin-like growth factor I receptor. Endocrinology 1999;140:1841-51
   PubMedGoogle Scholar
• Ferron M, Wei J, Yoshizawa T, et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 2010;142:296-308
   PubMed Web of Science ®Google Scholar
• Fulzele K, Riddle RC, DiGirolamo DJ, et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 2010;142:309-19
   PubMed Web of Science ®Google Scholar
• Thrailkill K, Bunn RC, Lumpkin C, et al. Loss of insulin receptor in osteoprogenitor cells impairs structural strength of bone. J Diabetes Res 2014;2014:703589
   PubMed Web of Science ®Google Scholar
• Díaz-López A, Bulló M, Juanola-Falgarona M, et al. Reduced serum concentrations of carboxylated and undercarboxylated osteocalcin are associated with risk of developing type 2 diabetes mellitus in a high cardiovascular risk population: a nested case-control study. J Clin Endocrinol Metab 2013;98:4524-31
   PubMedGoogle Scholar
• Gower BA, Pollock NK, Casazza K, et al. Associations of total and undercarboxylated osteocalcin with peripheral and hepatic insulin sensitivity and β-cell function in overweight adults. J Clin Endocrinol Metab 2013;98:E1173-80
   PubMedGoogle Scholar
• Fukunaga Y, Minamikawa J, Inoue D, et al. Does insulin use increase bone mineral density in patients with non-insulin-dependent diabetes mellitus? Arch Intern Med 1997;157:2668-9
   PubMedGoogle Scholar
• Weinstock RS, Goland RS, Shane E, et al. Bone mineral density in women with type II diabetes mellitus. J Bone Miner Res 1989;4:97-101
   PubMed Web of Science ®Google Scholar
• Conover CA, Lee PD, Riggs BL, et al. Insulin-like growth factor-binding protein-1 expression in cultured human bone cells: regulation by insulin and glucocorticoid. Endocrinology 1996;137:3295-301
   PubMed Web of Science ®Google Scholar
• Rosen CJ. Insulin-like growth factor I and bone mineral density: experience from animal models and human observational studies. Best Pract Res Clin Endocrinol Metab 2004;18:423-35
   PubMed Web of Science ®Google Scholar
• Horcajada-Molteni MN, Chanteranne B, Lebecque P, et al. Amylin and bone metabolism in streptozotocin-induced diabetic rats. J Bone Miner Res 2001;16:958-65
   PubMed Web of Science ®Google Scholar
• Dacquin R, Davey RA, Laplace C, et al. Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. J Cell Biol 2004;164:509-14
   PubMedGoogle Scholar
• Bouxsein ML, Rosen CJ, Turner CH, et al. Generation of a new congenic mouse strain to test the relationships among serum insulin-like growth factor I, bone mineral density, and skeletal morphology in vivo. J Bone Miner Res 2002;17:570-9
   PubMed Web of Science ®Google Scholar
• Zhang M, Xuan S, Bouxsein ML, et al. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem 2002;277:44005-12
   PubMed Web of Science ®Google Scholar
• Kanazawa I, Yamaguchi T, Sugimoto T. Serum insulin-like growth factor-I is a marker for assessing the severity of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Osteoporos Int 2011;22:1191-8
   PubMedGoogle Scholar
• Zhang Y, Papasian CJ, Deng H-W. Alteration of vitamin D metabolic enzyme expression and calcium transporter abundance in kidney involved in type 1 diabetes-induced bone loss. Osteoporos Int 2011;22:1781-8
   PubMedGoogle Scholar
• McCabe L, Zhang J, Raehtz S. Understanding the skeletal pathology of type 1 and 2 diabetes mellitus. Crit Rev Eukaryot Gene Expr 2011;21:187-206
   PubMed Web of Science ®Google Scholar
• Schwartz AV. Diabetes mellitus: does it affect bone? Calcif Tissue Int 2003;73:515-19
   PubMed Web of Science ®Google Scholar
• Hampson G, Evans C, Petitt RJ, et al. Bone mineral density, collagen type 1 alpha 1 genotypes and bone turnover in premenopausal women with diabetes mellitus. Diabetologia 1998;41:1314-20
   PubMedGoogle Scholar
• Verhaeghe J, van Herck E, Visser WJ, et al. Bone and mineral metabolism in BB rats with long-term diabetes. Decreased bone turnover and osteoporosis. Diabetes 1990;39:477-82
   PubMed Web of Science ®Google Scholar
• Frazer TE, White NH, Hough S, et al. Alterations in circulating vitamin D metabolites in the young insulin-dependent diabetic. J Clin Endocrinol Metab 1981;53:1154-9
   PubMed Web of Science ®Google Scholar
• Pino-Montes J, Benito GE, Fernández-Salazar MP, et al. Calcitriol improves streptozotocin-induced diabetes and recovers bone mineral density in diabetic rats. Calcif Tissue Int 2004;75:526-32
   PubMedGoogle Scholar
• Wang Y-H, Liu Y, Buhl K, et al. Comparison of the action of transient and continuous PTH on primary osteoblast cultures expressing differentiation stage-specific GFP. J Bone Miner Res 2005;20:5-14
   PubMedGoogle Scholar
• Motyl KJ, McCauley LK, McCabe LR. Amelioration of type I diabetes-induced osteoporosis by parathyroid hormone is associated with improved osteoblast survival. J Cell Physiol 2012;227:1326-34
   PubMedGoogle Scholar
• Schmid C, Schläpfer I, Peter M, et al. Growth hormone and parathyroid hormone stimulate IGFBP-3 in rat osteoblasts. Am J Physiol 1994;267:E226-33
   Google Scholar
• Porte D, Tuckermann J, Becker M, et al. Both AP-1 and Cbfa1-like factors are required for the induction of interstitial collagenase by parathyroid hormone. Oncogene 1999;18:667-78
   PubMed Web of Science ®Google Scholar
• Hamann C, Picke A-K, Campbell GM, et al. Effects of parathyroid hormone on bone mass, bone strength, and bone regeneration in male rats with type 2 diabetes mellitus. Endocrinology 2014;155:1197-206
   PubMed Web of Science ®Google Scholar
• Schnoke M, Midura SB, Midura RJ. Parathyroid hormone suppresses osteoblast apoptosis by augmenting DNA repair. Bone 2009;45:590-602
   PubMedGoogle Scholar
• Lozano D, de Castro LF, Dapía S, et al. Role of parathyroid hormone-related protein in the decreased osteoblast function in diabetes-related osteopenia. Endocrinology 2009;150:2027-35
   PubMedGoogle Scholar
• Rosen ED, MacDougald OA. Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol 2006;7:885-96
   PubMed Web of Science ®Google Scholar
• Duque G. Bone and fat connection in aging bone. Curr Opin Rheumatol 2008;20:429-34
   PubMed Web of Science ®Google Scholar
• Yaturu S, Humphrey S, Landry C, et al. Decreased bone mineral density in men with metabolic syndrome alone and with type 2 diabetes. Med Sci Monit 2009;15:CR5-9
   PubMedGoogle Scholar
• Botolin S. Increased bone adiposity and peroxisomal proliferator-activated receptor-gamma2 expression in type I diabetic mice. Endocrinology 2005;146:3622-31
   PubMed Web of Science ®Google Scholar
• Motyl KJ, Raetz M, Tekalur SA, et al. CCAAT/enhancer binding protein β-deficiency enhances type 1 diabetic bone phenotype by increasing marrow adiposity and bone resorption. Am J Physiol Regul Integr Comp Physiol 2011;300:R1250-60
   Google Scholar
• Vanella L, Kim DH, Asprinio D, et al. HO-1 expression increases mesenchymal stem cell-derived osteoblasts but decreases adipocyte lineage. Bone 2010;46:236-43
   PubMed Web of Science ®Google Scholar
• Rzonca SO, Suva LJ, Gaddy D, et al. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004;145:401-6
   PubMed Web of Science ®Google Scholar
• Maurin AC, Chavassieux PM, Frappart L, et al. Influence of mature adipocytes on osteoblast proliferation in human primary cocultures. Bone 2000;26:485-9
   PubMed Web of Science ®Google Scholar
• Elbaz A, Wu X, Rivas D, et al. Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro. J Cell Mol Med 2010;14:982-91
   PubMed Web of Science ®Google Scholar
• Coe LM, Irwin R, Lippner D, et al. The bone marrow microenvironment contributes to type I diabetes induced osteoblast death. J Cell Physiol 2011;226:477-83
   PubMedGoogle Scholar
• Steppan CM, Crawford DT, Chidsey-Frink KL, et al. Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept 2000;92:73-8
   PubMed Web of Science ®Google Scholar
• Reseland JE, Syversen U, Bakke I, et al. Leptin is expressed in and secreted from primary cultures of human osteoblasts and promotes bone mineralization. J Bone Miner Res 2001;16:1426-33
   PubMed Web of Science ®Google Scholar
• Cornish J, Callon KE, Bava U, et al. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol 2002;175:405-15
   PubMed Web of Science ®Google Scholar
• Luna R, Garcia-Mayor R V, Lage M, et al. High serum leptin levels in children with type 1 diabetes mellitus: contribution of age, BMI, pubertal development and metabolic status. Clin Endocrinol (Oxf) 1999;51:603-10
   PubMedGoogle Scholar
• Karagüzel G, Ozdem S, Boz A, et al. Leptin levels and body composition in children and adolescents with type 1 diabetes. Clin Biochem 2006;39:788-93
   PubMedGoogle Scholar
• Vasilkova O, Mokhort T, Sharshakova T, et al. Leptin is an independent determinant of bone mineral density in men with type 2 diabetes mellitus. Acta Diabetol 2011;48:291-5
   PubMedGoogle Scholar
• Hamrick MW, Della-Fera MA, Choi Y-H, et al. Leptin treatment induces loss of bone marrow adipocytes and increases bone formation in leptin-deficient ob/ob mice. J Bone Miner Res 2005;20:994-1001
   PubMedGoogle Scholar
• Martin A, de Vittoris R, David V, et al. Leptin modulates both resorption and formation while preventing disuse-induced bone loss in tail-suspended female rats. Endocrinology 2005;146:3652-9
   PubMed Web of Science ®Google Scholar
• Motyl KJ, McCabe LR. Leptin treatment prevents type I diabetic marrow adiposity but not bone loss in mice. J Cell Physiol 2009;218:376-84
   PubMed Web of Science ®Google Scholar
• Wu Y, Tu Q, Valverde P, et al. Central adiponectin administration reveals new regulatory mechanisms of bone metabolism in mice. Am J Physiol Endocrinol Metab 2014;306:E1418-30
   PubMed Web of Science ®Google Scholar
• Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007;130:456-69
   PubMed Web of Science ®Google Scholar
• Buday B, Pach FP, Literati-Nagy B, et al. Serum osteocalcin is associated with improved metabolic state via adiponectin in females versus testosterone in males. Gender specific nature of the bone-energy homeostasis axis. Bone 2013;57:98-104
   PubMed Web of Science ®Google Scholar
• Esser N, Legrand-Poels S, Piette J, et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract 2014;105(2):141-50
   PubMed Web of Science ®Google Scholar
• Bending D, Zaccone P, Cooke A. Inflammation and type one diabetes. Int Immunol 2012;24:339-46
   PubMed Web of Science ®Google Scholar
• Motyl KJ, Botolin S, Irwin R, et al. Bone inflammation and altered gene expression with type I diabetes early onset. J Cell Physiol 2009;218:575-83
   PubMed Web of Science ®Google Scholar
• Roszer T. Inflammation as death or life signal in diabetic fracture healing. Inflamm Res 2011;60:3-10
   PubMedGoogle Scholar
• Spranger J, Kroke A, Möhlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003;52:812-17
   PubMed Web of Science ®Google Scholar
• Irwin R, LaPres JJ, Kinser S, et al. Prolyl-hydroxylase inhibition and HIF activation in osteoblasts promotes an adipocytic phenotype. J Cell Biochem 2007;100:762-72
   PubMed Web of Science ®Google Scholar
• Oikawa A, Siragusa M, Quaini F, et al. Diabetes mellitus induces bone marrow microangiopathy. Arterioscler Thromb Vasc Biol 2010;30:498-508
   Google Scholar
• Burkhardt R, Moser W, Bartl R, et al. Is diabetic osteoporosis due to microangiopathy? Lancet 1981;1:844
   PubMed Web of Science ®Google Scholar
• Johnston SS, Conner C, Aagren M, et al. Association between hypoglycaemic events and fall-related fractures in Medicare-covered patients with type 2 diabetes. Diabetes Obes Metab 2012;14:634-43
   PubMed Web of Science ®Google Scholar
• Eller-Vainicher C, Zhukouskaya VV, Tolkachev YV, et al. Low bone mineral density and its predictors in type 1 diabetic patients evaluated by the classic statistics and artificial neural network analysis. Diabetes Care 2011;34:2186-91
   PubMed Web of Science ®Google Scholar
• Ali AA, Weinstein RS, Stewart SA, et al. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005;146:1226-35
   PubMed Web of Science ®Google Scholar
• Schwartz AV. TZDs and bone: a review of the recent clinical evidence. PPAR Res 2008;2008:297893
   PubMed Web of Science ®Google Scholar
• Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009;180:32-9
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 2005;48:1292-9
   PubMed Web of Science ®Google Scholar
• Zinman B, Haffner SM, Herman WH, et al. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab 2010;95:134-42
   PubMed Web of Science ®Google Scholar
• Cortizo AM, Sedlinsky C, McCarthy AD, et al. Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture. Eur J Pharmacol 2006;536:38-46
   PubMed Web of Science ®Google Scholar
• Gao Y, Xue J, Li X, et al. Metformin regulates osteoblast and adipocyte differentiation of rat mesenchymal stem cells. J Pharm Pharmacol 2008;60:1695-700
   PubMedGoogle Scholar
• Kanazawa I, Yamaguchi T, Yano S, et al. Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. Biochem Biophys Res Commun 2008;375:414-19
   PubMed Web of Science ®Google Scholar
• Ma P, Gu B, Ma J, et al. Glimepiride induces proliferation and differentiation of rat osteoblasts via the PI3-kinase/Akt pathway. Metabolism 2010;59:359-66
   PubMed Web of Science ®Google Scholar
• Jang WG, Kim EJ, Bae I-H, et al. Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2. Bone 2011;48:885-93
   PubMed Web of Science ®Google Scholar
• Schurman L, McCarthy AD, Sedlinsky C, et al. Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells. Exp Clin Endocrinol Diabetes 2008;116:333-40
   PubMed Web of Science ®Google Scholar
• Zhen D, Chen Y, Tang X. Metformin reverses the deleterious effects of high glucose on osteoblast function. J Diabetes Complications 2010;24:334-44
   PubMed Web of Science ®Google Scholar
• Mai Q-G, Zhang Z-M, Xu S, et al. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. J Cell Biochem 2011;112:2902-9
   PubMed Web of Science ®Google Scholar
• Jeyabalan J, Viollet B, Smitham P, et al. The anti-diabetic drug metformin does not affect bone mass in vivo or fracture healing. Osteoporos Int 2013;24:2659-70
   PubMed Web of Science ®Google Scholar
• Hegazy SK. Evaluation of the anti-osteoporotic effects of metformin and sitagliptin in postmenopausal diabetic women. J Bone Miner Metab 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Ljunggren Ö, Bolinder J, Johansson L, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab 2012;14:990-9
   PubMed Web of Science ®Google Scholar
• Bolinder J, Ljunggren Ö, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 2014;16:159-69
   PubMed Web of Science ®Google Scholar
• Nicodemus KK, Folsom AR. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 2001;24:1192-7
   PubMed Web of Science ®Google Scholar
• Lipscombe LL, Jamal SA, Booth GL, et al. The risk of hip fractures in older individuals with diabetes: a population-based study. Diabetes Care 2007;30:835-41
   PubMed Web of Science ®Google Scholar
• Ahmed LA, Joakimsen RM, Berntsen GK, et al. Diabetes mellitus and the risk of non-vertebral fractures: the Tromso study. Osteoporos Int 2006;17:495-500
   PubMed Web of Science ®Google Scholar
• Zhukouskaya VV, Eller-Vainicher C, Vadzianava VV, et al. Prevalence of morphometric vertebral fractures in patients with type 1 diabetes. Diabetes Care 2013;36:1635-40
   PubMed Web of Science ®Google Scholar
• Neumann T, Lodes S, Kästner B, et al. High serum pentosidine but not esRAGE is associated with prevalent fractures in type 1 diabetes independent of bone mineral density and glycaemic control. Osteoporos Int 2014;25:1527-33
   PubMedGoogle Scholar
• Forsén L, Meyer HE, Midthjell K, et al. Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trøndelag Health Survey. Diabetologia 1999;42:920-5
   PubMed Web of Science ®Google Scholar
• Neumann T, Sämann A, Lodes S, et al. Glycaemic control is positively associated with prevalent fractures but not with bone mineral density in patients with Type 1 diabetes. Diabet Med 2011;28:872-5
   PubMedGoogle Scholar
• Miao J, Brismar K, Nyrén O, et al. Elevated hip fracture risk in type 1 diabetic patients: a population-based cohort study in Sweden. Diabetes Care 2005;28:2850-5
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Yamaguchi T, Yamauchi M, et al. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res 2009;24:702-9
   PubMed Web of Science ®Google Scholar
• Schwartz AV. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 2011;305:2184-92
   PubMed Web of Science ®Google Scholar
• Strotmeyer ES, Cauley JA, Schwartz AV, et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med 2005;165:1612-17
   PubMed Web of Science ®Google Scholar
• Viégas M, Costa C, Lopes A, et al. Prevalence of osteoporosis and vertebral fractures in postmenopausal women with type 2 diabetes mellitus and their relationship with duration of the disease and chronic complications. J Diabetes Complications 2011;25:216-21
   PubMed Web of Science ®Google Scholar
• Melton LJ, Leibson CL, Achenbach SJ, et al. Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res 2008;23:1334-42
   PubMed Web of Science ®Google Scholar
• Schwartz AV, Sellmeyer DE, Ensrud KE, et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 2001;86:32-8
   PubMed Web of Science ®Google Scholar
• Gunczler P, Lanes R, Paoli M, et al. Decreased bone mineral density and bone formation markers shortly after diagnosis of clinical type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2001;14:525-8
   PubMed Web of Science ®Google Scholar
• Masse PG. Bone metabolic abnormalities associated with well-controlled type 1 diabetes (IDDM) in young adult women: a disease complication often ignored or neglected. J Am Coll Nutr 2010;29:419-29
   PubMed Web of Science ®Google Scholar
• Pastor MM, López-Ibarra PJ, Escobar-Jiménez F, et al. Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study. Osteoporos Int 2000;11:455-9
   PubMedGoogle Scholar
• Mastrandrea LD. Young women with type 1 diabetes have lower bone mineral density that persists over time. Diabetes Care 2008;31:1729-35
   PubMed Web of Science ®Google Scholar
• Pater A, Sypniewska G, Pilecki O. Biochemical markers of bone cell activity in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2010;23:81-6
   PubMed Web of Science ®Google Scholar
• Dobnig H. Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk. J Clin Endocrinol Metab 2006;91:3355-63
   PubMed Web of Science ®Google Scholar
• Manavalan JS, Cremers S, Dempster DW, et al. Circulating osteogenic precursor cells in type 2 diabetes mellitus. J Clin Endocrinol Metab 2012;97:3240-50
   PubMed Web of Science ®Google Scholar
• Iglesias P, Arrieta F, Piñera M, et al. Serum concentrations of osteocalcin, procollagen type 1 N-terminal propeptide and beta-CrossLaps in obese subjects with varying degrees of glucose tolerance. Clin Endocrinol (Oxf) 2011;75:184-8
   PubMed Web of Science ®Google Scholar
• Reyes-García R, Rozas-Moreno P, López-Gallardo G, et al. Serum levels of bone resorption markers are decreased in patients with type 2 diabetes. Acta Diabetol 2013;50:47-52
   PubMedGoogle Scholar
• García-Martín A, Rozas-Moreno P, Reyes-García R, et al. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2012;97:234-41
   PubMed Web of Science ®Google Scholar
• Shu A, Yin MT, Stein E, et al. Bone structure and turnover in type 2 diabetes mellitus. Osteoporos Int 2012;23:635-41
   PubMed Web of Science ®Google Scholar
• Achemlal L, Tellal S, Rkiouak F, et al. Bone metabolism in male patients with type 2 diabetes. Clin Rheumatol 2005;24:493-6
   PubMed Web of Science ®Google Scholar
• Basu R, Peterson J, Rizza R, et al. Effects of physiological variations in circulating insulin levels on bone turnover in humans. J Clin Endocrinol Metab 2011;96:1450-5
   PubMed Web of Science ®Google Scholar
• Jehle PM, Schulten K, Schulz W, et al. Serum levels of insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-1 to -6 and their relationship to bone metabolism in osteoporosis patients. Eur J Intern Med 2003;14:32-8
   PubMedGoogle Scholar
• Kanazawa I, Yamaguchi T, Yamamoto M, et al. Serum osteocalcin/bone-specific alkaline phosphatase ratio is a predictor for the presence of vertebral fractures in men with type 2 diabetes. Calcif Tissue Int 2009;85:228-34
   PubMedGoogle Scholar
• Yamamoto M, Yamauchi M, Sugimoto T. Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013;98:4030-7
   PubMed Web of Science ®Google Scholar
• Kayath MJ, Dib SA, Vieira JG. Prevalence and magnitude of osteopenia associated with insulin-dependent diabetes mellitus. J Diabetes Complications 1994;8:97-104
   PubMedGoogle Scholar
• Liu EY, Wactawski-Wende J, Donahue RP, et al. Does low bone mineral density start in post-teenage years in women with type 1 diabetes? Diabetes Care 2003;26:2365-9
   PubMed Web of Science ®Google Scholar
• Loureiro MB, Ururahy MAG, Freire-Neto FP, et al. Low bone mineral density is associated to poor glycemic control and increased OPG expression in children and adolescents with type 1 diabetes. Diabetes Res Clin Pract 2014;103:452-7
   PubMed Web of Science ®Google Scholar
• Brandao FR, Vicente EJ, Daltro CH, et al. Bone metabolism is linked to disease duration and metabolic control in type 1 diabetes mellitus. Diabetes Res Clin Pract 2007;78:334-9
   PubMedGoogle Scholar
• Lunt H, Florkowski CM, Cundy T, et al. A population-based study of bone mineral density in women with longstanding type 1 (insulin dependent) diabetes. Diabetes Res Clin Pract 1998;40:31-8
   PubMedGoogle Scholar
• Kemink SA, Hermus AR, Swinkels LM, et al. Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology. J Endocrinol Invest 2000;23:295-303
   PubMedGoogle Scholar
• López-Ibarra PJ, Pastor MM, Escobar-Jiménez F, et al. Bone mineral density at time of clinical diagnosis of adult-onset type 1 diabetes mellitus. Endocr Pract 2001;7:346-51
   PubMedGoogle Scholar
• Bridges MJ, Moochhala SH, Barbour J, et al. Influence of diabetes on peripheral bone mineral density in men: a controlled study. Acta Diabetol 2005;42:82-6
   PubMed Web of Science ®Google Scholar
• Strotmeyer ES, Cauley JA, Orchard TJ, et al. Middle-aged premenopausal women with type 1 diabetes have lower bone mineral density and calcaneal quantitative ultrasound than nondiabetic women. Diabetes Care 2006;29:306-11
   PubMedGoogle Scholar
• Hamilton EJ, Rakic V, Davis WA, et al. Prevalence and predictors of osteopenia and osteoporosis in adults with Type 1 diabetes. Diabet Med 2009;26:45-52
   PubMed Web of Science ®Google Scholar
• Danielson KK, Elliott ME, LeCaire T, et al. Poor glycemic control is associated with low BMD detected in premenopausal women with type 1 diabetes. Osteoporos Int 2009;20:923-33
   PubMed Web of Science ®Google Scholar
• Botushanov N, Yaneva M, Orbetzova M, Botushanova A. Bone mineral density in bulgarian patients with type 1 diabetes mellitus. J Osteoporos Phys Act 2014;2:113
   Google Scholar
• Ingberg C-M, Palmér M, Aman J, et al. Body composition and bone mineral density in long-standing type 1 diabetes. J Intern Med 2004;255:392-8
   PubMedGoogle Scholar
• Heap J, Murray MA, Miller SC, et al. Alterations in bone characteristics associated with glycemic control in adolescents with type 1 diabetes mellitus. J Pediatr 2004;144:56-62
   PubMed Web of Science ®Google Scholar
• Moyer-Mileur LJ, Dixon SB, Quick JL, et al. Bone mineral acquisition in adolescents with type 1 diabetes. J Pediatr 2004;145:662-9
   PubMed Web of Science ®Google Scholar
• Moyer-Mileur LJ, Slater H, Jordan KC, et al. IGF-1 and IGF-binding proteins and bone mass, geometry, and strength: relation to metabolic control in adolescent girls with type 1 diabetes. J Bone Miner Res 2008;23:1884-91
   PubMed Web of Science ®Google Scholar
• Saha MT, Sievänen H, Salo MK, et al. Bone mass and structure in adolescents with type 1 diabetes compared to healthy peers. Osteoporos Int 2009;20:1401-6
   PubMed Web of Science ®Google Scholar
• Bechtold S, Dirlenbach I, Raile K, et al. Early manifestation of type 1 diabetes in children is a risk factor for changed bone geometry: data using peripheral quantitative computed tomography. Pediatrics 2006;118:e627-34
   PubMed Web of Science ®Google Scholar
• Bechtold S, Putzker S, Bonfig W, et al. Bone size normalizes with age in children and adolescents with type 1 diabetes. Diabetes Care 2007;30:2046-50
   PubMedGoogle Scholar
• Roggen I, Gies I, Vanbesien J, et al. Trabecular bone mineral density and bone geometry of the distal radius at completion of pubertal growth in childhood type 1 diabetes. Horm Res Paediatr 2013;79:68-74
   PubMedGoogle Scholar
• Slade JM, Coe LM, Meyer RA, et al. Human bone marrow adiposity is linked with serum lipid levels not T1-diabetes. J Diabetes Complications 2012;26:1-9
   PubMedGoogle Scholar
• Camurdan MO, Ciaz P, Bideci A, et al. Role of hemoglobin A(1c), duration and puberty on bone mineral density in diabetic children. Pediatr Int 2007;49:645-51
   PubMedGoogle Scholar
• Heilman K, Zilmer M, Zilmer K, et al. Lower bone mineral density in children with type 1 diabetes is associated with poor glycemic control and higher serum ICAM-1 and urinary isoprostane levels. J Bone Miner Metab 2009;27:598-604
   PubMedGoogle Scholar
• Valerio G, Puente A, Puente A, et al. The lumbar bone mineral density is affected by long-term poor metabolic control in adolescents with type 1 diabetes mellitus. Horm Res 2002;58:266-72
   PubMed Web of Science ®Google Scholar
• Pascual J, Argente J, Lopez MB, et al. Bone mineral density in children and adolescents with diabetes mellitus type 1 of recent onset. Calcif Tissue Int 1998;62:31-5
   PubMed Web of Science ®Google Scholar
• Gunczler P, Lanes R, Paz-Martinez V, et al. Decreased lumbar spine bone mass and low bone turnover in children and adolescents with insulin dependent diabetes mellitus followed longitudinally. J Pediatr Endocrinol Metab 1998;11:413-19
   PubMed Web of Science ®Google Scholar
• Hadjidakis DJ, Raptis AE, Sfakianakis M, et al. Bone mineral density of both genders in Type 1 diabetes according to bone composition. J Diabetes Complications 2006;20:302-7
   PubMedGoogle Scholar
• Léger J, Marinovic D, Alberti C, et al. Lower bone mineral content in children with type 1 diabetes mellitus is linked to female sex, low insulin-like growth factor type I levels, and high insulin requirement. J Clin Endocrinol Metab 2006;91:3947-53
   PubMed Web of Science ®Google Scholar
• Simmons JH, Raines M, Ness KD, et al. Metabolic control and bone health in adolescents with type 1 diabetes. Int J Pediatr Endocrinol 2011;2011:13
   PubMedGoogle Scholar
• Leidig-Bruckner G, Grobholz S, Bruckner T, et al. Prevalence and determinants of osteoporosis in patients with type 1 and type 2 diabetes mellitus. BMC Endocr Disord 2014;14:33
   PubMed Web of Science ®Google Scholar
• De Liefde II, Klift M, Laet CEDH, et al. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int 2005;16:1713-20
   PubMed Web of Science ®Google Scholar
• Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: the Women’s Health Initiative Observational Study. J Clin Endocrinol Metab 2006;91:3404-10
   PubMed Web of Science ®Google Scholar
• Christensen JO, Svendsen OL. Bone mineral in pre- and postmenopausal women with insulin-dependent and non-insulin-dependent diabetes mellitus. Osteoporos Int 1999;10:307-11
   PubMed Web of Science ®Google Scholar
• Strotmeyer ES, Cauley JA, Schwartz AV, et al. Diabetes is associated independently of body composition with BMD and bone volume in older white and black men and women: the Health, Aging, and Body Composition Study. J Bone Miner Res 2004;19:1084-91
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcif Tissue Int 2009;84:45-55
   PubMed Web of Science ®Google Scholar
• Shan P-F, Wu X-P, Zhang H, et al. Bone mineral density and its relationship with body mass index in postmenopausal women with type 2 diabetes mellitus in mainland China. J Bone Miner Metab 2009;27:190-7
   PubMed Web of Science ®Google Scholar
• Sosa M, Saavedra P, Jódar E, et al. Bone mineral density and risk of fractures in aging, obese post-menopausal women with type 2 diabetes. The GIUMO Study. Aging Clin Exp Res 2009;21:27-32
   PubMed Web of Science ®Google Scholar
• Tao B, Liu J-M, Zhao H-Y, et al. Differences between measurements of bone mineral densities by quantitative ultrasound and dual-energy X-ray absorptiometry in type 2 diabetic postmenopausal women. J Clin Endocrinol Metab 2008;93:1670-5
   PubMedGoogle Scholar
• Tuominen JT, Impivaara O, Puukka P, et al. Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care 1999;22:1196-200
   PubMed Web of Science ®Google Scholar
• Anaforoglu I, Nar-Demirer A, Bascil-Tutuncu N, et al. Prevalence of osteoporosis and factors affecting bone mineral density among postmenopausal Turkish women with type 2 diabetes. J Diabetes Complications 2007;23:12-17
   Google Scholar
• Ma L, Oei L, Jiang L, et al. Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur J Epidemiol 2012;27:319-32
   PubMed Web of Science ®Google Scholar
• Hanley DA, Brown JP, Tenenhouse A, et al. Associations among disease conditions, bone mineral density, and prevalent vertebral deformities in men and women 50 years of age and older: cross-sectional results from the Canadian Multicentre Osteoporosis Study. J Bone Miner Res 2003;18:784-90
   PubMed Web of Science ®Google Scholar
• Register TC, Lenchik L, Hsu F-C, et al. Type 2 diabetes is not independently associated with spinal trabecular volumetric bone mineral density measured by QCT in the Diabetes Heart Study. Bone 2006;39:628-33
   PubMed Web of Science ®Google Scholar
• Rakic V, Davis WA, Chubb SAP, et al. Bone mineral density and its determinants in diabetes: the Fremantle Diabetes Study. Diabetologia 2006;49:863-71
   PubMed Web of Science ®Google Scholar
• Carr JJ, Register TC, Hsu F-C, et al. Calcified atherosclerotic plaque and bone mineral density in type 2 diabetes: the diabetes heart study. Bone 2008;42:43-52
   PubMed Web of Science ®Google Scholar
• Melton LJ, Riggs BL, Leibson CL, et al. A bone structural basis for fracture risk in diabetes. J Clin Endocrinol Metab 2008;93:4804-9
   PubMed Web of Science ®Google Scholar
• Petit MA, Paudel ML, Taylor BC, et al. Bone mass and strength in older men with type 2 diabetes: the Osteoporotic Fractures in Men Study. J Bone Miner Res 2010;25:285-91
   PubMed Web of Science ®Google Scholar
• Burghardt AJ, Issever AS, Schwartz AV, et al. High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010;95:5045-55
   PubMed Web of Science ®Google Scholar
• Pritchard JM, Giangregorio LM, Atkinson SA, et al. Association of larger holes in the trabecular bone at the distal radius in postmenopausal women with type 2 diabetes mellitus compared to controls. Arthritis Care Res (Hoboken) 2012;64:83-91
   PubMedGoogle Scholar
• Patsch JM, Li X, Baum T, et al. Bone marrow fat composition as a novel imaging biomarker in postmenopausal women with prevalent fragility fractures. J Bone Miner Res 2013;28:1721-8
   PubMed Web of Science ®Google Scholar
• Farr JN, Drake MT, Amin S, et al. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res 2014;29:787-95
   PubMed Web of Science ®Google Scholar
• Lecka-Czernik B. Safety of Anti-Diabetic Therapies on Bone. Clin Rev Bone Miner Metab 2013;11:49-58
   PubMedGoogle Scholar
• Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008;31:845-51
   PubMed Web of Science ®Google Scholar
• Borges JLC, Bilezikian JP, Jones-Leone AR, et al. A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naïve type 2 diabetes mellitus patients. Diabetes Obes Metab 2011;13:1036-46
   PubMed Web of Science ®Google Scholar
• Monami M, Dicembrini I, Antenore A, et al. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care 2011;34:2474-6
   PubMed Web of Science ®Google Scholar